Abstract
Changes in signal transduction are implicated in neuronal responses to the Alzheimer's amyloid-beta-peptide (Abeta), which include neurotransmitter systems and pathways involved in the maintenance of the nervous system. We report here that a new bifunctional compound IBU-PO, which combines a non-steroidal anti-inflammatory drug (NSAID) (Ibuprofen) and a cholinesterase (ChE) inhibitor (Octyl-Pyridostigmine), is neuroprotective against Abeta-neurotoxicity, and its activity is associated to Wnt signaling components in rat hippocampal and mouse cortical neurons. IBU-PO (0.01-1 microM) inhibits glycogen-synthase-kinase-3beta (GSK-3beta) and stabilizes cytoplasmic beta-catenin reverting the silencing of the Wnt pathway caused by Abeta-toxicity and GSK-3beta overexpression. In addition, IBU-PO enhances, dose-dependently, the non-amyloidogenic amyloid precursor protein (APP) cleavage by increasing secreted APP and decreasing endogenous Abeta1-40 in rat hippocampal neurons.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / metabolism
-
Alzheimer Disease / physiopathology
-
Amyloid beta-Peptides / antagonists & inhibitors*
-
Amyloid beta-Peptides / metabolism
-
Amyloid beta-Peptides / toxicity
-
Amyloid beta-Protein Precursor / drug effects
-
Amyloid beta-Protein Precursor / metabolism
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Brain / drug effects
-
Brain / metabolism
-
Brain / physiopathology
-
Cells, Cultured
-
Cholinesterase Inhibitors / pharmacology*
-
Cholinesterase Inhibitors / therapeutic use
-
Cytoskeletal Proteins / drug effects
-
Cytoskeletal Proteins / metabolism
-
Disease Models, Animal
-
Down-Regulation / drug effects
-
Down-Regulation / physiology
-
Drug Compounding
-
Glycogen Synthase Kinase 3 / antagonists & inhibitors
-
Glycogen Synthase Kinase 3 / genetics
-
Glycogen Synthase Kinase 3 / metabolism
-
Glycogen Synthase Kinase 3 beta
-
Ibuprofen / pharmacology
-
Ibuprofen / therapeutic use
-
Intercellular Signaling Peptides and Proteins / metabolism*
-
Mice
-
Mice, Transgenic
-
Neuroprotective Agents / pharmacology*
-
Peptide Fragments / antagonists & inhibitors
-
Peptide Fragments / metabolism
-
Pyridinium Compounds / pharmacology*
-
Pyridinium Compounds / therapeutic use
-
Pyridostigmine Bromide / pharmacology
-
Pyridostigmine Bromide / therapeutic use
-
Rats
-
Rats, Sprague-Dawley
-
Signal Transduction / physiology
-
Trans-Activators / drug effects
-
Trans-Activators / metabolism
-
Wnt Proteins
-
beta Catenin
Substances
-
1-(8-(2-(4-isobutylphenyl)propionyl)octyl)-3-N,N-dimethylcarbamoyl pyridinium bromide
-
Amyloid beta-Peptides
-
Amyloid beta-Protein Precursor
-
Anti-Inflammatory Agents, Non-Steroidal
-
CTNNB1 protein, mouse
-
Cholinesterase Inhibitors
-
Ctnnb1 protein, rat
-
Cytoskeletal Proteins
-
Intercellular Signaling Peptides and Proteins
-
Neuroprotective Agents
-
Peptide Fragments
-
Pyridinium Compounds
-
Trans-Activators
-
Wnt Proteins
-
amyloid beta-protein (1-40)
-
beta Catenin
-
Glycogen Synthase Kinase 3 beta
-
Gsk3b protein, mouse
-
Gsk3b protein, rat
-
Glycogen Synthase Kinase 3
-
Pyridostigmine Bromide
-
Ibuprofen